New cell therapy targets stubborn leukemia after failed transplant
NCT ID NCT07280494
Summary
This study is testing a new type of cell therapy called CD7-targeted CAR-T cells for patients with T-cell leukemia or lymphoma. The goal is to see if this therapy is safe and effective for patients who still have small amounts of cancer left after receiving a stem cell transplant from a donor. The therapy involves collecting a patient's own immune cells, modifying them in a lab to better target cancer, and then infusing them back into the patient.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD7+ T-ALL/LBL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China, 100044, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.